The complaint filed against the NASDAQ-listed firm alleges that ADMA Biologics violated sections 10(b) and 20(a) of the Securities Exchange Act. According to the court filing, the company allegedly misled the market by failing to disclose a significant related-party transaction. Furthermore, the suit claims management engaged in channel stuffing—a practice of inflating sales figures to create a false impression of robust commercial activity. These actions reportedly rendered the company’s public statements materially misleading throughout the specified class period.
In section Releases
ADMA Biologics Faces Class Action Over Alleged Securities Violations
Investors who purchased ADMA Biologics shares between August 9, 2024, and March 25, 2026, are being urged to step forward as a class action lawsuit accuses the company of systemic financial deception. The DJS Law Group is currently organizing the litigation, setting an August 10, 2026, deadline for potential participants.
Shareholders who incurred financial losses during this timeframe are encouraged to contact the DJS Law Group to discuss their legal standing. While the firm is seeking to appoint a lead plaintiff to represent the class, participation in the recovery process does not strictly require such an appointment. The litigation highlights concerns regarding corporate governance and the transparency of ADMA's reporting practices during the tenure of the alleged misconduct.
Comments (0)
No comments yet. Be the first!